CTOs on the Move


 
Lyte is a technology platform fans to safely buy, sell and exchange tickets to live events and for venues and event owners to take control of their ticketing experience.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.lyte.com
  • 580 Howard Street
    San Francisco, CA USA 94105
  • Phone: N/A

Executives

Name Title Contact Details
Gregory Fulton
Chief Product Officer Profile

Funding

Lyte raised $15M on 10/08/2019
Lyte raised $33M on 12/17/2020

Similar Companies

OpenText

OpenText software applications manage content or unstructured data for large companies, government agencies, and professional service firms.

Ardham Technologies

Keeping IT Simple

Calpont

Calpont Corporation is a provider of scalable, high-performance analytic databases enabling ultra-fast, deep analysis of massive data sets. Its InfiniDB Enterprise Edition is the emerging choice for demanding data warehouse, Business Intelligence, reporting, analytic application and data mart deployments. Known for its quick implementation time, unmatched operational simplicity and unparalleled value, InfiniDB provides rapid access to critical business data for data-intensive businesses including those in the SaaS, retail, telecommunications and government industries.

Sales Impact Academy

Salesimpact.io is a sales acceleration company that offers an AI-powered sales productivity platform. Their sales acceleration technologies include sales enablement, sales coaching, and sales training services. Their platform delivers metrics-driven in...

Kapost

Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.